Anita T. Shaffer

Linking a targeted drug to a chemotherapy shows promise for treating metastatic triple-negative breast cancer.

Adding Perjeta (pertuzumab) to postoperative Herceptin (trastuzumab) improved survival in certain patients with breast cancer.

Some newly diagnosed patients with prostate cancer reduced their risk of death with earlier use of Zytiga, according to two trials presented at the ASCO Annual Meeting.

A recent study proved an online program to be helpful in reducing anxiety in many newly diagnosed patients.

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer.

According to results from a recent study, Keytruda had longer overall survival (OS) when compared to chemotherapy for patients with bladder cancer.

In some cases, genomic blood analysis may be effective enough to replace cancer biopsies.

The best use of liquid biopsies in late-stage non–small cell lung cancer (NSCLC) will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

Scientists are enthusiastic about new technology that will be able to edit human genes.

In a recent study, patients with lung cancer who used an online app to track their symptoms saw a higher overall survival rate than those who didn't.

Though more research still needs to be done, potential for liquid biopsies was shown in a study involving 15,000 patients who represented a multitude of cancer types.

Recent findings may make way for a less expensive treatment option for patients with metastatic breast cancer.

Checkpoint blockade immunotherapies like Keytruda are increasing the OS rates for patients with advanced melanoma.

In the fast-moving world of melanoma treatment, new therapeutic options for patients with metastatic disease are emerging faster than oncology researchers can establish guidelines for their optimal clinical use. That is raising questions about which should be the firstline choice in metastatic melanoma — targeted drugs or immunotherapy — and how these drugs should be sequenced.

In an interview with CURE, John L. Marshall emphasized that treating GI cancers is a "team sport."

For Shvon Lowe, an invitation from a friend to attend the Sisters Network 5K turned into being something much bigger in her life.

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.

The addition of the PD-1 inhibitor Keytruda (pembrolizumab) to an established multiple myeloma regimen elicited responses in 76 percent of 17 patients with relapsed/refractory disease.

Adjuvant whole brain radiation therapy (WBRT) dramatically increases the incidence of cognitive decline without survival benefit in patients with small brain metastases from other tumor types.

When cancers that originate elsewhere cause small metastases in the brain, initial treatment should not routinely be followed by whole brain radiation therapy, because that strategy dramatically increases the chances of cognitive decline without improving survival outcomes.

An ambitious clinical trial set to start in July will match patients to treatments based on molecular abnormalities, rather than cancer types, testing 20 targeted drugs at once.

When melanoma metastacizes, the lymph node to which it has spread is typically removed. But what if micrometastases are found in other nearby lymph nodes? Should patients undergo a complete dissection, or removal, of all the nodes in the area?

A two-pronged strategy combining the PARP inhibitor Lynparza and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with TNBC and for patients with high-grade serous ovarian cancer.

CURE editor-in-chief and breast oncologist, Debu Tripathy, reviews the top breast cancer research highlights from 2014.

Looking at prior treatment and efficacy data, researchers finds significant benefit with radiotherapy when given to older patients with hormone-negative invasive breast cancer who had undergone breast-conserving surgery.

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype called metaplastic breast cancer, was one of the top studies presented at the Miami Breast Cancer Conference this year.

The Food and Drug Administration is evaluating proposals for new indications for at least 17 oncology medicines, according to Friends of Cancer Research, an advocacy group that aims to get patients cutting-edge treatments as safely and quickly as possible.